Eli Lilly And Company

This early-phase study tested the safety of combining two drugs, abemaciclib and darolutamide, in 10 men with prostate cancer that had spread and stopped responding to standard hormone therapy. The goal was to see if the combination was safe enough to study further. Participants …

This early-stage study tested whether adding a new drug (LY3841136) to an existing weight-loss medication (tirzepatide) is safe and tolerable. 96 healthy overweight or obese adults took part over about 42 weeks. The main goal was to check for side effects, not to prove weight los…

This early-stage study tested an experimental drug called LY3437943 against a placebo in 85 people with obesity. The goal was to see how the drug affects calorie intake, energy use, and appetite while participants followed a reduced-calorie diet. The study lasted up to 6 months a…

This study tested a drug called mirikizumab in 63 children aged 2 to 17 with moderate to severe ulcerative colitis, a disease causing inflammation in the colon. The goal was to see if the drug could help control the disease and improve symptoms. Participants had already tried oth…

This study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% im…

This study looked at how a new medicine, LY3209590, is processed in the bodies of 15 children with type 2 diabetes. Each child received one dose, and researchers measured the drug levels in their blood over time. The goal was to understand how the drug is absorbed and removed, no…

This study tested a drug called ramucirumab, given with standard chemotherapy, for children and young adults with a rare cancer called desmoplastic small round cell tumor (DSRCT) that had come back or not responded to treatment. The goal was to see if the combination could slow t…

This early-phase study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if the drug is safe and how it affects cancer cells before the participants had surgery. The study lasted up to 2.5 …

This study tested a once-daily pill called orforglipron in 546 adults with type 2 diabetes whose blood sugar was not well controlled despite using insulin (with or without other diabetes medications). The goal was to see if adding orforglipron could safely lower blood sugar level…

This study looked at whether starting tirzepatide before Ramadan helps adults with type 2 diabetes manage their blood sugar while fasting. 166 participants took the medicine once a week. Researchers measured changes in blood sugar, weight, and safety events like low blood sugar.

This early-stage study tested a new daily pill called LY3549492 in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and side effects over about 18 weeks. Participants had diabetes for at least 6 months and were on diet, exercise, or stable metformin. This…

This study tested whether mirikizumab can help people with moderate to severe ulcerative colitis stay in remission. About 1,300 patients who improved during an earlier 12-week study received either mirikizumab or a placebo for 40 weeks. The goal was to see if the drug could maint…

This study tested a once-daily medication called LY3549492 to help adults with obesity or overweight lose weight. About 288 participants took either the drug or a placebo for around one year. The main goal was to see how much weight they lost and how safe the treatment was.

This early-stage study tested a single dose of the investigational drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to measure how the drug moves through the body. Participants were randomly assigne…

This study tested an experimental drug called remternetug in 1667 people with early symptoms of Alzheimer's disease. The main goal was to see if the drug could safely clear amyloid plaques from the brain, a hallmark of Alzheimer's. Participants received either the drug or a place…

This study tested whether adding a weight-loss drug (tirzepatide) to a standard arthritis drug (ixekizumab) helps people with psoriatic arthritis who are overweight or obese. 279 adults with active psoriatic arthritis and a BMI of 27 or higher took part. The goal was to see if th…

This study looked at whether adding a second drug (mibavademab) to the weight-loss medication tirzepatide helps people with obesity lose more weight than tirzepatide alone. About 392 adults with a BMI between 30 and 40 took part. The trial lasted about 74 weeks and involved up to…

This early-phase study tested a new drug called LY3039478 in 247 adults with advanced or metastatic cancer, including lymphoma. The main goals were to find a safe dose and see if the drug could shrink tumors. While the drug showed some activity, it is not a cure and requires furt…

This study tested a weekly medicine called tirzepatide to help people with obesity or overweight keep weight off after losing it. About 441 adults took part. The goal was to see if the drug helps maintain weight loss better than a placebo.

This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for sig…

This study tested a drug called donanemab (LY3002813) in 272 people with early-stage Alzheimer's disease. The goal was to see if it is safe and can slow down memory and thinking problems. Participants received either the drug or a placebo, and researchers measured changes in thei…

This study tested a connected insulin management platform in 36 people with type 1 or type 2 diabetes who use insulin. The goal was to see if the platform helped them take their insulin doses on time and keep their blood sugar in a healthy range. Participants used a continuous gl…

This study tested the drug mirikizumab in 172 adults with moderate-to-severe ulcerative colitis who still had bowel urgency despite other treatments. The main goal was to see if the drug reduces the sudden, urgent need to use the bathroom. Participants were followed for 36 weeks …

This study tested an experimental drug called LY3372689 in 327 people with early symptoms of Alzheimer's disease. The goal was to see if the drug is safe and can slow down memory loss and daily function problems. Participants received either the drug or a placebo, and their progr…

This study tested whether baricitinib, a pill taken daily, can safely help regrow hair in adults with severe or very severe alopecia areata, an autoimmune condition causing patchy or total scalp hair loss. Over 600 participants received either baricitinib or a placebo for 36 week…

This study tested a new medication called Mazdutide to help adults with obesity or overweight manage their weight. 179 participants received either the drug or a placebo over about 62 weeks. The main goal was to see how much weight they lost after 32 weeks.

This study tested the drug orforglipron in 120 adults with obesity or overweight (but not diabetes) to see how it changes body fat compared to a placebo. Participants were followed for about 8 months. The main goal was to measure changes in visceral fat, the deep belly fat linked…

This study tested a new once-daily pill, orforglipron, against another daily pill (oral semaglutide) in adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. About 1,700 participants took one of the two pills for roughly 61 weeks. The main goal…

This study looked at how safe Lyumjev (a fast-acting insulin) is for adults with type 2 diabetes in India. About 150 people who already use multiple daily insulin injections took part. The main goal was to see how many had low blood sugar episodes over 26 weeks of treatment.

This study compared a once-daily pill called orforglipron to insulin glargine in about 2,749 adults with type 2 diabetes who were also overweight or obese and had increased heart or kidney risk. The main goal was to see if orforglipron could prevent major heart problems like hear…

This study tested a once-weekly injection called retatrutide in over 2,300 adults with obesity or overweight who do not have diabetes. The goal was to see if it helps with weight loss and improves related issues like knee arthritis and sleep apnea. Participants received the drug …

This study tested an oral drug called LOXO-305 in 87 Chinese adults with certain types of lymphoma or chronic lymphocytic leukemia that had already been treated with standard therapies. The goal was to see how safe and effective the drug is. Participation could last up to four ye…

This study tested a once-daily oral medication called orforglipron to see if it helps adults with obesity or overweight and type 2 diabetes lose weight. Over 1600 participants took either the drug or a placebo for about 77 weeks. The main goal was to measure changes in body weigh…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This study tested a once-daily pill called orforglipron in 559 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. The goal was to see if the drug safely lowers blood sugar levels compared to a placebo over about 54 weeks. Participant…

This study tested a once-weekly injection called retatrutide in 537 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either the drug or a placebo for about 11 months. The main goal was to see if retatrutide lo…

This study tested a new medicine called tirzepatide in 206 Chinese adults with type 2 diabetes. Participants received either the drug or a placebo to see if it safely lowers blood sugar levels. The goal was to measure how well the drug controls diabetes over time.

This study looked at the long-term safety and effectiveness of lebrikizumab for people with moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants were followed for up to 33 months. The goal was to see how many people stopped treatment due to side effects and how …

This study tested two medications, tirzepatide and semaglutide, to see which helps adults with obesity or overweight lose more weight. About 750 people without diabetes took part over 74 weeks. The goal was to measure how much weight they lost and how many achieved significant we…

This study tested a drug called lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug safely improves eczema symptoms, like redness and itching, over 24 weeks. Researchers measured how many participants had at l…

This study tested a new drug (LY2157299) alone or combined with standard chemotherapy (lomustine) in 158 adults with recurrent glioblastoma, an aggressive brain cancer. The goal was to see if the new drug could help patients live longer or slow tumor growth compared to chemothera…

This study tested two doses of baricitinib, a pill, in 784 adults with severe or very severe alopecia areata, a condition causing major hair loss. The goal was to see if the drug could regrow scalp hair significantly. While baricitinib may help control hair loss, it is not a cure…

This study tested a new drug called LY3871801 in 164 adults with moderate-to-severe rheumatoid arthritis. The goal was to see if it reduces joint swelling and pain better than a placebo. Participants took the drug or a dummy pill for several weeks, and doctors measured changes in…

This study tested a new once-daily pill called orforglipron against an existing drug, dapagliflozin, in adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. About 962 participants took either orforglipron or dapagliflozin for roughly 46 week…

This study tested a medicine called tirzepatide in children and teenagers (ages 10 to 17) with type 2 diabetes that was not well controlled by metformin or insulin. The goal was to see if the drug safely lowers blood sugar levels better than a placebo. The study lasted about 60 w…

This study tested a once-daily pill called orforglipron to see if it helps people with obesity or overweight maintain weight loss they achieved with injectable drugs like Zepbound or Wegovy. About 376 adults who had completed a prior weight-loss trial took either orforglipron or …

This study tested whether retatrutide can improve kidney function in 146 adults who are overweight or obese and have chronic kidney disease, some also with type 2 diabetes. Participants received the drug or a placebo for about 31 weeks. The goal was to see if the drug helps prese…

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer drugs in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if the co…

This study tested an experimental oral drug, LY3972406, in 33 adults with moderate-to-severe plaque psoriasis. The goal was to see if it safely reduces skin redness, thickness, and scaling. Participants were randomly assigned to receive the drug or a placebo, and results were mea…

This early-stage study tested a new drug called LY3532226 in 132 people with obesity to see if it is safe and how the body processes it. Participants received weekly or monthly doses, and researchers monitored side effects and drug levels in the blood. The goal was to gather safe…

This study tested a once-weekly injection called retatrutide in 445 people with obesity or overweight who also have knee osteoarthritis. The goal was to see if it helps with weight loss and reduces knee pain. The trial lasted about 77 weeks and compared the drug to a placebo.

This early-stage study tested a new medicine called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check for side effects and see how the body processes the drug. Participants took the medicine for several weeks and had regular blood tests to measure drug level…

This early-stage study tested a new drug called LY3502970 in 72 healthy overweight and obese adults. The main goal was to check the drug's safety and how the body processes it. Participants were monitored for up to 42 days. This research helps determine if the drug is safe enough…

This early-stage study tested a new oral drug, LY3549492, in 92 Japanese adults—some with type 2 diabetes and some healthy. The main goal was to see if the drug is safe and what side effects it might cause. Researchers also measured how much drug gets into the blood and how the b…

This early-stage study tested a new drug called eloralintide, given alone or with tirzepatide, in 188 adults with overweight or obesity. The main goals were to check safety, side effects, and how the drugs move through the body. Participants received weekly injections under the s…

This study tested the safety of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Researchers monitored side effects and how the body processes the drugs over several months. The goal was to see if the…

This early-stage study looked at how a single dose of the experimental drug LY3526318 changes blood flow in the skin of healthy women. Sixteen participants received the drug or a placebo, and their skin blood flow was measured after applying a cinnamon-like substance. The goal wa…

This study looked at how the body absorbs, breaks down, and gets rid of a drug called LY3502970. Ten healthy adults took the drug by mouth and also received a radioactive version through a vein. The goal was to measure how much of the oral dose reaches the bloodstream. This is a …

This study looked at how two different versions of the drug LY3502970 behave in the body. Thirty-nine healthy adults took part to help researchers measure drug levels in the blood and check for any safety issues. The goal was to gather information, not to treat a disease.

This study tested a new drug called LY3522348 in 65 healthy adults to see if it is safe and what side effects it might cause. Researchers also measured how much drug gets into the blood and how fast the body gets rid of it. The study had two parts, lasting up to 6 or 8 weeks each…

This study tested how healthy adults absorb different forms of bimagrumab, given alone or together with tirzepatide. The goal was to compare the body's concentration of these drugs, not to treat any disease. 125 healthy participants took part, and the study lasted about 4.5 month…

This completed Phase 1 study looked at how orforglipron, an experimental drug, changes the way the body processes several common medications (digoxin, simvastatin, rosuvastatin, acetaminophen, and midazolam) in 50 healthy overweight or obese adults. The goal was to measure drug l…

This study looked at how two common drugs, itraconazole and rifampin, change the way the body processes selpercatinib, a cancer treatment. Twenty-four healthy adults took part to help researchers understand these interactions. The goal was to gather safety and drug-level informat…

This study tested a new drug called LY3502970 in 34 healthy adults to see how the body absorbs and processes it after eating or fasting. Researchers took blood samples to measure drug levels and checked for any side effects. The goal was to gather safety and dosing information, n…

This study tested how a single dose of selpercatinib changes the amount of rosuvastatin in the blood of 28 healthy adults. The goal was to see if taking these two drugs together could lead to higher or lower levels of rosuvastatin, which might affect safety or effectiveness. Part…

This study looked at how imlunestrant enters the bloodstream and leaves the body in women with liver problems compared to healthy women. About 27 women took part, and the goal was to understand how liver function affects the drug's processing. No treatment was given for any disea…

This study looked at how a new drug, LY4064809, enters the blood and how long it takes the body to get rid of it. Ten healthy Chinese adults took the drug by mouth and were monitored for about 21 days. The goal was to measure drug levels and check for any safety issues.

This study looked at how the body processes a drug called LY4064809. Seven healthy adults received the drug by mouth and by IV to compare how much enters the bloodstream. The goal was to understand the drug's absorption, not to treat any disease. Participants stayed at a research…

This study looked at how the drug LY3502970 moves through the body in people with healthy kidneys compared to those with kidney problems. Researchers measured the amount of drug in the blood and how long it stays. The goal was to understand if kidney function changes how the drug…

This study looked at how a single dose of the drug LY3502970, tagged with a tiny amount of radioactivity, is absorbed and removed from the body. Six healthy men took one dose, and researchers measured the drug and its breakdown products in blood, urine, and stool over up to 8 wee…

This study looked at how the drug LY3502970 moves through the body in people with different levels of liver function. 29 adults with healthy livers or mild, moderate, or severe liver impairment received a single dose. Researchers measured drug levels in the blood to understand ho…

This early-stage study tested a new drug called LY3876602 in 74 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers measured drug levels in blood and spinal fluid. The study did not aim to treat an…

This early-stage study tested the safety and how the body handles a new drug called LY3451838. It involved 53 healthy adults who received either a single dose into a vein or just under the skin. The main goal was to check for side effects and measure how the drug moves through th…

This study looked at how a high-fat meal and a common stomach-acid drug (omeprazole) change the way the body absorbs and clears selpercatinib, a cancer medication. Twenty healthy adults took single doses under different conditions. The goal was to learn the best way to take the d…

This study looked at how the cancer drug selpercatinib changes the way the body processes repaglinide, a diabetes medication. Sixteen healthy adults took part over 12 days. The goal was to measure drug levels in the blood, not to treat any disease.

This study looked at how a drug called imlunestrant affects the way the body processes other medications in healthy women who cannot become pregnant. Researchers measured how imlunestrant changed the levels of several common drugs, including repaglinide, omeprazole, dextromethorp…

This early-stage study looked at how the experimental drug LY3526318 enters and leaves the body in 16 healthy adults. Participants took either a single dose or multiple doses by mouth. The goal was to check safety and how the body processes the drug, not to treat any disease.

This study tested several new versions of insulin lispro in 54 healthy volunteers to see how quickly the body absorbs and clears them, and whether they cause side effects. The goal was purely to gather safety and drug-level information, not to treat any disease. Participants were…

This study looked at how the antibiotic clarithromycin changes the amount of LY3502970 in the blood of 26 healthy adults. Participants took LY3502970 alone and then with clarithromycin to see if there is a drug interaction. The study was completed and lasted about 85 days per per…

This early-stage study looked at how healthy adults absorb and process the experimental drug LY4268989. Researchers measured drug levels in the blood and checked for side effects. The study included Japanese and Chinese participants to see if ethnicity affects drug handling.

This early-stage study tested the safety and tolerability of a new drug called LY4060874 in 121 healthy adults. Participants were monitored for side effects and how the drug moved through their bodies. The study did not aim to treat any disease, but to gather important safety inf…

This study looked at how the drug olomorasib moves through the body of 120 healthy adults. Participants took the drug by mouth and stayed overnight at the research center for 10 nights over about 7 weeks. The goal was to measure drug levels in the blood, not to treat any disease.

This study looked at how two different capsule forms of the drug olomorasib are absorbed into the blood, and whether food changes that absorption. It involved 191 healthy Japanese participants over about 6 weeks. The goal was to gather information, not to treat any disease.

This study looked at how the drug LY3537982 moves through the body in people with different levels of kidney function. Researchers compared 32 participants with normal kidneys to those with moderate or severe kidney problems. The goal was to find the right dose for people with ki…

This study looked at how the drug quinidine changes the amount of orforglipron in the blood of 27 healthy adults. Participants took both drugs by mouth, and researchers measured drug levels over time. The goal was to understand how the body processes orforglipron when taken with …

This study looked at how healthy male volunteers absorb, process, and eliminate a drug called LY4065967. Sixteen men took part in two parts over about two months. The goal was to understand the drug's movement in the body, not to treat any disease.

This study looked at how the drug cyclosporine changes the amount of an experimental drug (LY3502970) in the blood of 32 healthy adults. Participants took LY3502970 alone and then with cyclosporine to compare drug levels and check for side effects. The goal was to gather safety a…

This study tested how a new tablet form of the experimental drug LY3502970 enters the blood and leaves the body compared to an older capsule form. It involved 26 healthy adults over about 6 months. The goal was to gather safety and drug-level information, not to treat any disease…

This early-stage study tested a new drug called LY3985863 in 24 healthy Chinese adults to see if it is safe and what side effects it might cause. Participants received multiple doses under the skin or a placebo. Blood tests helped researchers understand how the body processes the…

This study tested two different ways to give a single dose of remternetug: using an autoinjector or a prefilled syringe. The goal was to see how much of the drug gets into the bloodstream and how fast the body clears it. 72 healthy adults took part, and the study lasted about 155…

This study looked at how the drug olomorasib enters the blood and how long it takes the body to remove it in people with mild, moderate, or severe liver problems compared to healthy people. 46 adults took a single dose and were monitored for up to 6 weeks. The goal was to underst…

This study looked at how the antifungal drug fluconazole changes the amount of a cancer drug called olomorasib in the blood. Fifteen healthy adults stayed at a research center for 12 nights over about 7 weeks. The goal was to measure drug levels, not to treat any disease.

This study looked at how a drug called LY3484356 enters the bloodstream and leaves the body. Sixteen healthy women who cannot become pregnant took a single dose with a radioactive tracer. Researchers measured the drug in blood, urine, and stool to understand its breakdown and eli…

This study looked at how two different versions of the drug LY4064809 enter the bloodstream and how long the body takes to remove them. It involved 24 healthy adults who stayed at a research center for about a month. The goal was to gather information, not to treat any disease.

This study looked at how the body handles the drug selpercatinib in people with different levels of kidney function. 37 adults, some with kidney problems and some healthy, took a single dose. Researchers measured drug levels in the blood and urine to see if kidney impairment chan…

This study looked at how food and certain other drugs (omeprazole, itraconazole, carbamazepine) affect the amount of a new medicine called LY3484356 in the blood of healthy women who cannot become pregnant. The goal was to understand how the body processes the drug, not to treat …

This study looked at whether a single dose of the cancer drug Selpercatinib changes the heart's electrical activity (QT interval) in 32 healthy adults. Participants received the drug, a placebo, or a positive control in random order. The goal was to check for heart rhythm side ef…

This study tested the safety and side effects of a single dose of lebrikizumab (given as a shot under the skin) compared to a placebo in 24 healthy Chinese adults. Researchers also measured how fast the drug enters the blood and how long the body takes to remove it. The study did…

This study looked at how taking imlunestrant multiple times changes the way the body handles midazolam, a drug used to measure liver enzyme activity. Twenty healthy women who cannot become pregnant took part. The goal was to understand drug interactions and safety, not to treat a…

This study looked at how the drug selpercatinib changes the way the body handles midazolam, a common sedative. Sixteen healthy adults took both drugs, and researchers measured drug levels in the blood. The goal was to gather safety and interaction data, not to treat any disease.

This early-stage study tested whether a new drug called LY3985297 is safe and well-tolerated in 140 healthy adults. Participants received either a single dose or multiple doses of the drug through an IV or injection under the skin. The study also measured how much drug gets into …

This study looked at how a drug called LY3537031 moves through the body in people with different levels of kidney function. Researchers compared 31 adults with normal kidneys to those with kidney problems or end-stage kidney disease. The goal was simply to gather information, not…

This study looked at how well two different autoinjectors deliver the drug mirikizumab into the bloodstream of healthy people. About 500 healthy adults received a single injection under the skin using either a standard 1-mL autoinjector or a newer 2-mL version. The goal was to se…